Mustang Bio Faces Nasdaq Delisting Warning

TL;DR

Nasdaq's giving MBIO the boot unless they fix things by May '25. Board shake-up too.

AI Summary

Mustang Bio, Inc. announced on November 12, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The company has until May 12, 2025, to regain compliance. Additionally, the company reported changes in its board of directors and officer appointments.

Why It Matters

This delisting warning could negatively impact Mustang Bio's stock price and its ability to raise capital, potentially affecting its ongoing research and development efforts.

Risk Assessment

Risk Level: high — The company is facing a delisting warning from Nasdaq, indicating significant financial or operational challenges that could lead to its stock being removed from the exchange.

Key Numbers

• May 12, 2025 — Compliance Deadline (The company has until this date to meet Nasdaq's continued listing requirements.)

Key Players & Entities

• Mustang Bio, Inc. (company) — Registrant
• Nasdaq Stock Market (company) — Listing Exchange
• November 12, 2024 (date) — Date of delisting notice
• May 12, 2025 (date) — Deadline to regain compliance

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share MBIO Nasdaq Capital Marke
• $1.00 — Company's common stock had closed below $1.00 per share for 30 consecutive business d
• $2.5 million — ce with both the Bid Price Rule and the $2.5 million stockholders' equity requirement set fo

Filing Documents

• tm2428644d1_8k.htm (8-K) — 27KB
• 0001104659-24-119756.txt ( ) — 195KB
• mbio-20241112.xsd (EX-101.SCH) — 3KB
• mbio-20241112_lab.xml (EX-101.LAB) — 33KB
• mbio-20241112_pre.xml (EX-101.PRE) — 22KB
• tm2428644d1_8k_htm.xml (XML) — 3KB

01 Notice of Delisting

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 16, 2024, Mustang Bio, Inc. (the "Company") was notified by the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the bid price for the Company's common stock had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company no longer satisfied Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted a 180-calendar day grace period to regain compliance with the Bid Price Rule, through November 12, 2024. The Company did not regain compliance with the Bid Price Rule by November 12, 2024, and, accordingly, on November 13, 2024, the Staff issued a delist determination with respect to the deficiency, as required by the Nasdaq Listing Rules. Notwithstanding the above, and as previously disclosed, on October 29, 2024, the Company attended a hearing before a Nasdaq Hearings Panel (the "Panel"), at which the Company presented its plan to evidence compliance with both the Bid Price Rule and the $2.5 million stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule," and together with the Bid Price Rule, the "Rules"). By decision dated November 8, 2024, the Panel granted the Company's request for an extension through January 31, 2025, to demonstrate compliance with the Bid Price Rule, and through February 18, 2025, to demonstrate compliance with the Equity Rule. Accordingly, the Staff's November 13, 2024, notice has no immediate impact on the Company's listing at this time. The Company is considering all options available to it to regain compliance with the Rules within the extension periods granted by the Panel; however, there can be no assurance that the Company will be able to do so.

02 Departure of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 12, 2024, James Murphy resigned as the Company's Interim Chief Financial Officer . Mr. Murphy's resignation was not a result of any disagreement on any matter relating to the Company's operations, policies or practices. On November 15, 2024, the Company's Board of Directors (the "Board") appointed Manuel Litchman, M.D., President and Chief Executive Officer of the Company, as the Company's Interim Chief Financial Officer, effective immediately. Dr. Litchman, age 70, has been the Company's President and Chief Executive Officer, and a member of the Board, since April 2017, and previously served as Interim Chief Financial Officer in December 2023 and January 2024. There were no arrangements or understandings between Dr. Litchman and any other person pursuant to which Dr. Litchman was appointed as an officer. Dr. Litchman does not have any family relationships subject to disclosure under Item 401(d) of Regulation S-K or any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Company has not entered into, adopted or commenced any new, or amended any existing compensation plans, arrangements, or employment agreements with Dr. Litchman in connection with these appointments.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mustang Bio, Inc. (Registrant) Date: November 15, 2024 By: /s/ Manuel Litchman, M.D. Name: Manuel Litchman, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR